论文部分内容阅读
探讨ＭＴＴ法药敏试验对卵巢癌临床化疗的指导意义。采用改良ＭＴＴ法检测了６ 株卵巢癌细胞对１０ 种化疗药物１０ 种不同浓度的药物敏感性。通过卵巢癌细胞株对化疗药物的量效关系曲线求出药物的ＩＤ５０ 值及ＡＵＣａｔＩＤ５０ 值来判断药效。结果表明，①药敏试验结果与卵巢癌细胞株的病理类型、原代细胞取材部位无肯定关联，但各卵巢癌细胞株对化疗药物的敏感性有显著性差异（Ｐ＜０－００１）；②以ＩＤ５０ 法判定，ＩＦＭ 对５ 株卵巢癌细胞有效，ＣＰＭ、ＡＣＴＤ 对４ 株有效，ＰＭＭＣ、ＶＢＬ对２ 株有效，以ＡＵＣ法判定，ＩＦＭ 对６ 株有效，ＮＫ６１１ 对４ 株有效，ＣＰＭ 对３ 株有效。提示改良ＭＴＴ法药敏试验结果为卵巢癌临床化疗提供了客观依据。
To explore the MTT method of drug sensitivity test for the clinical significance of ovarian cancer chemotherapy. Six strains of ovarian cancer cells were tested for their sensitivity to ten different concentrations of 10 chemotherapeutic drugs using a modified MTT assay. Ovarian cancer cell lines through the dose-effect relationship of chemotherapy drugs to determine the drug ID50 value and AUCatID50 value to determine the efficacy. The results showed that ① the results of drug susceptibility test showed no relationship with the pathological types of primary ovarian cancer cell lines and primary tumor cells, but the sensitivity of ovarian cancer cell lines to chemotherapeutics was significantly different (P <0-001). ② ID50 method to determine, IFM effective on 5 ovarian cancer cells, CPM, ACT D effective on 4, P MMC, VBL on the two effective, determined by the AUC method, IFM effective against 6, NK611 on 4 Effective, CPM is effective against 3 strains. It is suggested that the modified MTT assay results provide an objective basis for the clinical chemotherapy of ovarian cancer.